← All drugs
Drug · FAERS side-effect profile with label screen

Mirtazapine side effects: what 91,033 FDA adverse event reports show

Mirtazapine · 1,206 reaction terms · 368,001 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Who reports

91,033 reports · 84% serious · 13,998 with death outcome · 58% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Mirtazapine tablets are indicated for the treatment of major depressive disorder (MDD) in adults . Mirtazapine tablets are indicated for the treatment of major depressive disorder (MDD) in adults. (1)

FDA label, Indications and Usage

What it is

Mirtazapine tablets contain mirtazapine, USP. Mirtazapine has a tetracyclic chemical structure and belongs to the piperazino-azepine group of compounds. It is designated 1,2,3,4,10,14b-hexahydro- 2-methylpyrazino [2,1-a] pyrido [2,3-c] [2] benzazepine and has the empirical formula of C 17 H 19 N 3 .

FDA label, Description section

Boxed warning

SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1)] .

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled — boxed warning 1Labeled adverse reaction 3Labeled (related wording) 7Reporting / coding artifact 3Lab value / disease marker 1Not in label — unassessed 25
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,166 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Amaurosis fugax18347.4
40.4–55.6ROR 47.5 · calibrated p 2e-5 ✓
39.2 EB05 34.7 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious n=183 · 100% cliniciannot reported in cached trials
Delusion of grandeur7244.0
34.2–56.7ROR 44.1 · calibrated p 4e-5 ✓
36.7 EB05 30.1 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=71 · ♀ 0% (drug 58%) · 100% cliniciannot reported in cached trials
Anticholinergic syndrome16526.5
22.6–31.1ROR 26.6 · calibrated p 5e-4 ✓
23.8 EB05 20.9 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=164 · ♀ 100% (drug 58%) · 100% cliniciannot reported in cached trials
Cogwheel rigidity10725.9
21.2–31.7ROR 26.0 · calibrated p 6e-4 ✓
23.3 EB05 19.8 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=107 · ♀ 100% (drug 58%) · 100% cliniciannot reported in cached trials
Intrusive thoughts11325.5
21.0–31.0ROR 25.6 · calibrated p 7e-4 ✓
23.0 EB05 19.6 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=112 · ♀ 0% (drug 58%)not reported in cached trials
Depersonalisation/derealisation disorder13521.0
17.6–25.1ROR 21.0 · calibrated p 0.002 ✓
19.3 EB05 16.7 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=133not reported in cached trials
Gastric ph decreased7618.3
14.5–23.1ROR 18.3 · calibrated p 0.003 ✓
16.9 EB05 13.9 · IC025 +3.6
3/3 methods agree
Lab value / disease markerserious n=74 · ♀ 100% (drug 58%) · 100% cliniciannot reported in cached trials
Serotonin syndrome1,33217.2
16.3–18.2ROR 17.4 · calibrated p 0.004 ✓
16.0 EB05 15.3 · IC025 +3.9
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 14.8 · serious PRR 10.9not reported in cached trials
Product monitoring error7913.4
10.7–16.8ROR 13.4 · calibrated p 0.012 ✓
12.5 EB05 10.3 · IC025 +3.2
3/3 methods agree
Reporting / coding artifactserious n=79 · 100% cliniciannot reported in cached trials
Bezoar7112.5
9.8–15.8ROR 12.5 · calibrated p 0.016 ✓
11.7 EB05 9.5 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=71 · ♀ 100% (drug 58%) · 100% cliniciannot reported in cached trials
Derealisation10712.1
9.9–14.7ROR 12.1 · calibrated p 0.017 ✓
11.4 EB05 9.6 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=104 · ♀ 100% (drug 58%)not reported in cached trials
H1n1 influenza6811.6
9.1–14.8ROR 11.6 · calibrated p 0.021 ✓
10.8 EB05 8.8 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious n=68 · ♀ 100% (drug 58%) · 100% clinicianNCT00535288: 2/158 (1.3%) on Mirtazapine; 15/314 (4.8%) control
Sopor64211.6
10.7–12.5ROR 11.6 · calibrated p 0.019 ✓
11.0 EB05 10.3 · IC025 +3.3
3/3 methods agree
Not in label — unassessedage-adj. PRR 8.6 · serious PRR 7.6 · 96% cliniciannot reported in cached trials
Sleep paralysis7011.5
9.1–14.6ROR 11.5 · calibrated p 0.021 ✓
10.8 EB05 8.7 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious n=66 · ♀ 100% (drug 58%)not reported in cached trials
Poisoning deliberate43811.3
10.3–12.5ROR 11.4 · calibrated p 0.021 ✓
10.8 EB05 10.0 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious PRR 7.4 · 100% cliniciannot reported in cached trials
Intentional self-injury92111.0
10.3–11.7ROR 11.1 · calibrated p 0.023 ✓
10.5 EB05 9.9 · IC025 +3.3
3/3 methods agree
Reporting / coding artifactserious PRR 7.3not reported in cached trials
Accidental death8310.8
8.6–13.4ROR 10.8 · calibrated p 0.027 ✓
10.1 EB05 8.3 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=83 · 100% cliniciannot reported in cached trials
Suspected suicide21010.6
9.2–12.1ROR 10.6 · calibrated p 0.027 ✓
10.1 EB05 8.9 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=210 · 100% cliniciannot reported in cached trials
Multiple drug overdose intentional14210.4
8.8–12.3ROR 10.5 · calibrated p 0.029 ✓
9.9 EB05 8.6 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious n=141 · 100% cliniciannot reported in cached trials
Neuroleptic malignant syndrome51510.4
9.5–11.3ROR 10.4 · calibrated p 0.028 ✓
9.9 EB05 9.2 · IC025 +3.2
3/3 methods agree
Not in label — unassessedage-adj. PRR 8.8 · serious PRR 6.9not reported in cached trials
Noninfective gingivitis6210.3
8.0–13.3ROR 10.3 · calibrated p 0.031 ✓
9.6 EB05 7.7 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=58 · ♀ 100% (drug 58%) · 100% consumernot reported in cached trials
Hyperkinesia8810.1
8.1–12.5ROR 10.1 · calibrated p 0.033 ✓
9.5 EB05 7.9 · IC025 +2.9
3/3 methods agree
Labeled adverse reaction
exact term
serious n=85not reported in cached trials
Inappropriate antidiuretic hormone secretion4159.7
8.8–10.8ROR 9.8 · calibrated p 0.035 ✓
9.3 EB05 8.6 · IC025 +3.1
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 6.4 · 94% cliniciannot reported in cached trials
Psychomotor retardation1119.5
7.9–11.5ROR 9.5 · calibrated p 0.040 ✓
9.0 EB05 7.6 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=111 · 100% cliniciannot reported in cached trials
Wrong patient received product1139.4
7.8–11.4ROR 9.4 · calibrated p 0.041 ✓
8.9 EB05 7.6 · IC025 +2.8
3/3 methods agree
Reporting / coding artifactserious n=113 · 100% cliniciannot reported in cached trials
Illusion669.4
7.4–12.1ROR 9.4 · calibrated p 0.042 ✓
8.8 EB05 7.1 · IC025 +2.7
3/3 methods agree
Not in label — unassessedserious n=62 · ♀ 0% (drug 58%)not reported in cached trials
Coma scale abnormal1109.2
7.6–11.1ROR 9.2 · calibrated p 0.045 ✓
8.7 EB05 7.4 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=110 · 100% cliniciannot reported in cached trials
Jc virus infection619.1
7.0–11.8ROR 9.1 · calibrated p 0.047 ✓
8.4 EB05 6.8 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=61 · ♀ 0% (drug 58%) · 100% cliniciannot reported in cached trials
Feeling of despair1748.9
7.7–10.4ROR 8.9 · calibrated p 0.048 ✓
8.5 EB05 7.5 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=169not reported in cached trials
Bradykinesia2148.7
7.6–10.0ROR 8.8 · calibrated p 0.051
8.4 EB05 7.4 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=196not reported in cached trials
Akathisia (inner restlessness)4878.5
7.8–9.3ROR 8.5 · calibrated p 0.055
8.2 EB05 7.6 · IC025 +2.9
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 7.3not reported in cached trials
Cleft palate698.5
6.7–10.8ROR 8.5 · calibrated p 0.059
7.9 EB05 6.4 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=69 · 100% cliniciannot reported in cached trials
Muscle rigidity4268.5
7.7–9.3ROR 8.5 · calibrated p 0.055
8.2 EB05 7.5 · IC025 +2.9
3/3 methods agree
Not in label — unassessedage-adj. PRR 7.4 · serious PRR 6.1not reported in cached trials

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Suicidality7,0626.86.6–6.9signal
Extrapyramidal2,5325.65.4–5.9signal
Hyponatraemia1,9215.65.4–5.9signal
Depression4,1663.43.3–3.6signal
Rhabdomyolysis / myopathy1,0843.12.9–3.3signal
Fall / fracture4,3802.72.6–2.7signal
Arrhythmia / qt2,1882.62.5–2.7signal
Seizure2,0732.42.3–2.6signal
Pancreatitis7012.01.9–2.2raised
Gi bleeding1,4941.91.8–2.0raised
Kidney injury3,5451.81.7–1.9raised
Serious infection5,2181.61.5–1.6raised
Anaemia1,9601.51.4–1.6raised
Severe cutaneous reaction4841.51.4–1.6raised
Liver injury1,9241.51.4–1.5raised
Venous thromboembolism1,3351.41.3–1.5raised

Trial evidence (ClinicalTrials.gov)

✓ Trial adverse-event data found on ClinicalTrials.gov

Largest completed trials with posted results that list Mirtazapine as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (1 of 40 signal terms matched).

Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Nausea5,0281.5
1.4–1.5ROR 1.5 · calibrated p 0.640
1.5 EB05 1.4 · IC025 +0.5Labeled adverse reaction
exact term
age-adj. PRR 1.2 · serious PRR 1.6NCT00560833: 5/155 (3.2%) on Mirtazapine; 17/317 (5.4%) control
Fatigue (tiredness)4,9041.5
1.4–1.5ROR 1.5 · calibrated p 0.630
1.5 EB05 1.4 · IC025 +0.5Labeled adverse reaction
exact term
age-adj. PRR 1.2 · serious PRR 1.5NCT00535288: 23/158 (14.6%) on Mirtazapine; 9/314 (2.9%) control
Drug ineffective (drug did not work)4,7860.8
0.8–0.9ROR 0.8 · calibrated p 0.199
0.8 EB05 0.8 · IC025 -0.3
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 1.0 · serious PRR 1.2not reported in cached trials
Fall4,1682.9
2.8–3.0ROR 3.0 · calibrated p 0.625
2.9 EB05 2.8 · IC025 +1.5
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.3 · serious PRR 2.3not reported in cached trials
Diarrhoea (diarrhea)4,1111.5
1.4–1.5ROR 1.5 · calibrated p 0.640
1.5 EB05 1.4 · IC025 +0.5Labeled adverse reaction
exact term
age-adj. PRR 1.2 · serious PRR 1.4not reported in cached trials
Off label use (used outside approved label)3,9981.1
1.0–1.1ROR 1.1 · calibrated p 0.349
1.1 EB05 1.0 · IC025 +0.0Reporting / coding artifactage-adj. PRR 1.0 · serious PRR 1.1not reported in cached trials
Toxicity to various agents3,8365.4
5.2–5.5ROR 5.6 · calibrated p 0.182
5.3 EB05 5.1 · IC025 +2.3
3/3 methods agree
Not in label — unassessedage-adj. PRR 5.0 · serious PRR 3.7 · 92% cliniciannot reported in cached trials
Dizziness3,5851.7
1.6–1.7ROR 1.7 · calibrated p 0.763
1.7 EB05 1.6 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.7NCT00535288: 13/158 (8.2%) on Mirtazapine; 12/314 (3.8%) control
Anxiety3,5792.9
2.8–3.0ROR 3.0 · calibrated p 0.629
2.9 EB05 2.8 · IC025 +1.5
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.8 · serious PRR 2.5not reported in cached trials
Dyspnoea (shortness of breath)3,5371.4
1.4–1.5ROR 1.5 · calibrated p 0.616
1.4 EB05 1.4 · IC025 +0.5Labeled adverse reaction
exact term
age-adj. PRR 1.1 · serious PRR 1.2not reported in cached trials
Death3,4500.9
0.9–1.0ROR 0.9 · calibrated p 0.255
0.9 EB05 0.9 · IC025 -0.2
PRR-only: not supported by EBGM or IC
Outcome field, not a reactionage-adj. PRR 1.0 · serious PRR 0.6not reported in cached trials
Drug interaction3,3454.9
4.8–5.1ROR 5.1 · calibrated p 0.225
4.9 EB05 4.7 · IC025 +2.2
3/3 methods agree
Reporting / coding artifactage-adj. PRR 3.8 · serious PRR 3.6not reported in cached trials
Vomiting3,3171.6
1.6–1.7ROR 1.7 · calibrated p 0.743
1.6 EB05 1.6 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.5not reported in cached trials
Depression3,2963.4
3.2–3.5ROR 3.4 · calibrated p 0.499
3.3 EB05 3.2 · IC025 +1.7
3/3 methods agree
Labeled — boxed warning
synonym match
age-adj. PRR 3.0 · serious PRR 2.8not reported in cached trials
Headache3,1581.2
1.1–1.2ROR 1.2 · calibrated p 0.418
1.2 EB05 1.1 · IC025 +0.2Labeled adverse reaction
exact term
age-adj. PRR 1.0 · serious PRR 1.3NCT00535288: 13/158 (8.2%) on Mirtazapine; 33/314 (10.5%) control

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Mirtazapine ↔ Suicidal Ideation.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Mirtazapine?

In FDA FAERS, the most frequently co-reported reaction terms for Mirtazapine are nausea, fatigue, fall, diarrhoea, toxicity to various agents, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Mirtazapine have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1)] .

Do FAERS signals prove that Mirtazapine causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.